RxDoctor Payments Data

Joshua Olson, MD

Ophthalmology · Rochester, MNNPI 1710143334

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 27 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$663
  • AbbVie$202
  • Sight Sciences, Inc.$161
  • Microsurgical Technology, Inc.$133
  • The Cameron-ehlen Group, Inc.$104
  • Glaukos Corporation$72
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon15$663
AbbVie(2 entities)4$202
Sight Sciences, Inc.2$161
Microsurgical Technology, Inc.1$133
The Cameron-ehlen Group, Inc.1$104
Glaukos Corporation3$72
Johnson & Johnson Surgical Vision, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,349 in reported general payments places this provider in the 70th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$128,373
Medicare patients
424
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast85$79,976
RestasisCyclosporine88$75,493
Cyclosporine81$28,025
Prednisolone Acetate265$10,499
TyrvayaVarenicline Tartrate14$8,863
AzasiteAzithromycin18$6,707
Latanoprost536$6,559
Ketorolac Tromethamine140$6,442
Travoprost44$5,822
TafluprostTafluprost/Pf26$5,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat199$4,168
MoxifloxacinMoxifloxacin Hcl216$4,070
LumiganBimatoprost12$3,742
Dorzolamide-TimololDorzolamide/Timolol/Pf24$2,981
Bromfenac Sodium18$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$202$81,916115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →